Fig. 6.

Celecoxib and 2,5-dimethyl-celecoxib (DMC) enhanced Kv7 currents in guinea pig ASMCs. A: time course of celecoxib (10 μM)-induced enhancement of endogenous Kv7 currents recorded in ASMCs at −20 mV holding voltage (C = 23 pF, representative of 5 similar experiments). A break in the recording (10 min) is indicated by 2 vertical gray lines. B: I-V relationships of Kv7 currents recorded from −4 mV holding voltage in ASMCs before (control, ●), during treatment with 10 μM celecoxib (○), and after 5-min treatment with the Kv7 channel blocker XE991 (10 μM, ▲, n = 4). C: averaged fractional conductance plots calculated from steady-state Kv7 currents measured in ASMCs in control (●) and in the presence of 10 μM celecoxib (○) fitted to a Boltzmann distribution (V_0.5 = −32.4 ± 2.2 mV in control, V_0.5 = −39.8 ± 1.5 mV in the presence of 10 μM celecoxib; n = 5, P < 0.05, paired Student's t-test). D: time course of Kv7 current enhancement by DMC (10 μM) recorded at −20 mV holding voltage (C = 13 pF, representative of 3 similar experiments). E: I-V relationships of Kv7 currents recorded in ASMCs before (control, ●), during treatment with 10 μM DMC (○), and after 10 min of washout (▲, n = 3). F: averaged fractional conductance plots calculated from steady-state Kv7 currents measured in ASMCs in control (●) and in the presence of 10 μM DMC (○) fitted to a Boltzmann distribution (V_0.5 = −28.7 ± 2.2 mV in control, V_0.5 = −43.1 ± 4.6 mV in the presence of 10 μM DMC; n = 3, P < 0.05, paired Student's t-test).